800 million vitamin varieties! Zhengda Pharmaceuticals won the first review

Pharmaceutical Network February 2, the State Drug Administration's official website shows that Zhengda Pharmaceutical (Qingdao) Afa osteotisol softgels to supplement the application was approved, is the first domestic product evaluation enterprises.
2018 sales of Afa osteobolic alcohol capsules in China's public medical institutions exceeded 800 million yuan, a slight decline in 2019, according to the Company's internal network data.
the first half of 2020, Afa orthopedicol softgels with a market share of 5.70% into the vitamin products TOP5.
January 29, 2021 drug approval documents to be received information release-1 data show that afa osteoalphrine is an active vitamin D, mainly used for osteoporosis, adrenal osteopathy, thyroid hypertension and other adaptive disorders.
Source: One-click access to Minet data show that in 2018, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of Afa osteool capsules more than 800 million yuan, a slight decline in 2019.
In the first half of 2020, Afa orthopedicol softgels with 5.70% market share among the vitamin products TOP5, domestic manufacturers have Kunming Baker Norton Pharmaceuticals, Shanghai Xinyi Yan'an Pharmaceuticals and other 6 import manufacturers have Teva Pharmaceuticals and Leo.
the evaluation of consistency, at present, Kunming Baker Norton Pharmaceuticals and Shanghai Xinyi Yan'an Pharmaceutical Co., Ltd. in the evaluation of supplementary applications in the review and approval (in the drug review center).
source: official website of the State Drug Administration, Mi Net database